# M7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/m7r2-addendum-application-of-the-principles-of-the-ich-m7-guideline-to-calculation-of-compound-specific-acceptable-intakes-guidance-for-industry/868061ca-5806-48f0-9ad8-f904ab7868fc

> FDA guidance document: M7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES:  Guidance for Industry. Issue date: July 25, 2023. Get complete insights and analysis.

---

## Details

- Title: M7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-07-25
- Last Changed: 2023-07-25
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2022-D-0055">FDA-2022-D-0055</a>

## Related Documents

- [Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/formal-meetings-between-the-fda-and-sponsors-or-applicants-of-bsufa-products-guidance-for-industry/8a1d80ed-d462-41f3-b1cd-7df78736a49b)
- [Assessing User Fees Under the Biosimilar User Fee Amendments of 2022:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/assessing-user-fees-under-the-biosimilar-user-fee-amendments-of-2022-guidance-for-industry/4fbb7da7-e7da-4ffb-a835-53f0fa1a9dda)
- [Questions and Answers | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/questions-and-answers-m7r2-assessment-and-control-of-dna-reactive-mutagenic-impurities-in-pharmaceuticals-to-limit-potential-carcinogenic-risk-guidance-for-industry/c4192f88-a166-40a9-900f-0f22f5a5373a)